The Pediatric Hodgkin Lym phoma Consortium, which in cludes St. Jude Children's
Research Hospital, Stanford University, Dana–Farber Cancer Institute/Bos ton Children's …

BACKGROUND In the last two decades, it has become evident that secondary leukemias
after Hodgkin's disease (HD) are mainly caused by the treatment with alkylating agents …

Background Children and adolescents with early-stage classical Hodgkin lymphoma have a
5-year event-free survival of 90% or more with vincristine, etoposide, prednisone, and …

Background Oncology drug shortage is associated with increased patient adverse events
and decreased enrollment on clinical trials for adult patients; however, the impact of …

CONSIDERING THAT curative therapy has been avail-able for Hodgkin's disease for more
than 30 years, oncologists treating children and adolescents with the disease have an …

Abstract Abstract 767 Introduction: Optimal therapy for favorable risk HL in children and
adolescents continues to evolve. Although the great majority of children will be cured, the …

Importance To date, there is no well-defined standard of care for early-stage pediatric
Hodgkin lymphoma (HL), which may include chemotherapy alone or combined modality …

Purpose To minimize the risk of late effects in pediatric Hodgkin lymphoma (HL) by omitting
radiotherapy (RT) in patients in complete remission (CR) after chemotherapy and reducing …

Background For two decades now combined chemo-radiotherapy has been preferred in
most of the studies on childhood Hodgkin's disease (HD), because combined modality is the …

The successful integration of clinical trials into pediatric oncology has led to steady
improvement in the 5-year survival rate for children diagnosed with Hodgkin lymphoma (HL) …